Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-18 7:48 pm Purchase |
2021-01-27 | 13G | Catalyst Biosciences, Inc. CBIO |
Stonepine Capital Management, LLC | 543,781 6.900% |
332,221 (+157.03%) |
Filing History |
| 2021-02-16 06:14 am Purchase |
2020-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
ACUTA CAPITAL PARTNERS LLC | 344,172 6.100% |
344,172 (New Position) |
Filing History |
| 2021-02-12 5:00 pm Sale |
2020-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
Stonepine Capital Management, LLC | 211,561 3.800% |
-51,920 (-19.71%) |
Filing History |
| 2021-02-12 3:18 pm Purchase |
2020-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
Nantahala Capital Management, LLC | 472,924 8.400% |
201,200 (+74.05%) |
Filing History |
| 2021-02-12 2:42 pm Purchase |
2021-02-16 | 13G | Catalyst Biosciences, Inc. CBIO |
Dimensional Fund Advisors LP | 200,334 3.600% |
15,195 (+8.21%) |
Filing History |
| 2021-02-11 4:57 pm Sale |
2020-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
Integrated Core Strategies (US) LLC | 173,399 3.100% |
-8,477 (-4.66%) |
Filing History |
| 2021-02-10 3:04 pm Purchase |
2021-01-31 | 13G | Catalyst Biosciences, Inc. CBIO |
BlackRock Inc. BLK |
342,912 4.400% |
1,302 (+0.38%) |
Filing History |
| 2021-02-10 10:39 am Purchase |
2020-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
The Vanguard Group | 249,072 4.450% |
96,116 (+62.84%) |
Filing History |
| 2021-02-04 5:28 pm Sale |
2020-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
Mangrove Partners Master Fund Ltd. | 0 0.000% |
-173,068 (Position Closed) |
Filing History |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
BlackRock Inc. BLK |
341,610 6.100% |
271,614 (+388.05%) |
Filing History |
| 2020-08-06 11:13 am Purchase |
2020-06-17 | 13G | Catalyst Biosciences, Inc. CBIO |
Assenagon Asset Management S.A. | 282,589 6.390% |
222,819 (+372.79%) |
Filing History |
| 2020-08-06 11:13 am Purchase |
2020-06-18 | 13G | Catalyst Biosciences, Inc. CBIO |
Assenagon Asset Management S.A. | 59,771 1.070% |
59,771 (New Position) |
Filing History |
| 2020-08-05 4:09 pm Purchase |
2020-03-03 | 13G | Catalyst Biosciences, Inc. CBIO |
Stonepine Capital Management, LLC | 263,481 6.000% |
263,481 (New Position) |
Filing History |
| 2020-08-05 09:23 am Unchanged |
2020-06-22 | 13D | Catalyst Biosciences, Inc. CBIO |
22NW LP | 186,560 34.000% |
0 (Unchanged) |
Filing History |